Pergolide monotherapy in the treatment of early PD: A randomized, controlled study

Neurology

Volumn 53, Issue 3, 1999, Pages 573-579

  Barone, Paolo ^h   Bravi, D ^a   Bermejo Pareja, F ^b   Marconi, R ^c   Kulisevsky, J ^d   Malagu S ^e   Weiser, R ^f   Rost, N ^g  

^a ELI LILLY   (Italy)

^b HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^c MISERICORDIA HOSPITAL   (Italy)

^d HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^e L Pierantoni Hospital   (Italy)

^f MORRISTON HOSPITAL   (United Kingdom)

^g ELI LILLY AND COMPANY   (United States)

^h UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; LEVODOPA; PERGOLIDE; PLACEBO;

ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NAUSEA; NEUROTOXICITY; ORAL DRUG ADMINISTRATION; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SUPRAVENTRICULAR PREMATURE BEAT; VERTIGO; VOMITING; XEROSTOMIA;

EID: 0033546648     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/wnl.53.3.573     Document Type: Article

References (37)

1. Fahn S. Adverse effects of levodopa. In: Olanow CW, Lieberman AN, eds. The scientific basis for the treatment of Parkinson's disease. Park Ridge, IL: Parthenon Publishing, 1992:89-112.
2. Quinn N, Critchley P, Mardsen CD. Young onset Parkinson's disease. Mov Disord 1987;2:73-91.
3. Block G, Liss C, Reines S, Irr J, Nibbelink D. Comparison of immediate-release and controlled release carbidopa-levodopa in Parkinson's disease. A multicenter 5-year study. The CR First Study Group. Eur Neurol 1997;37:23-27.
4. Mouradian MM, Juncos IL, Fabbrini G, et al. Motor fluctuations in Parkinson's disease: central pathophysiological mechanisms, part II. Ann Neurol 1988;24:372-378.
5. Bravi D, Mouradian MM, Roberts JW, et al. Wearing-off fluctuations in Parkinson's disease: contribution of postsynaptic mechanisms. Ann Neurol 1994;36:27-31.
6. Murer MG, Dziewczapolski G, Menalled LB, et al. Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesions. Ann Neurol 1998;43:561-575.
7. Spencer JP, Jenner A, Aruoma OI, et al. Intense oxidative DNA damage promoted by L-dopa and its metabolites: implications for neurodegenerative disease. FEBS Lett 1994;353-246-250.
8. Nutt JG. Levodopa: rational and irrational pharmacology. Ann Neurol 1994;36:4-5.
9. Olanow CW. A rationale for dopamine agonists as primary therapy for Parkinson's disease. Can J Neurol Sci 1992;19: 108-112.
10. Olanow CW, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease: treatment guidelines. Neurology 1998;50(suppl 3):S1-S57.
11. Fuller RW, Clemens JA. Pergolide: a dopamine agonist at both D1 and D2 receptors. Life Sci 1991;49:925-930.
12. Pezzoli G, Martignoni E, Pacchetti C, et al. Pergolide compared with bromocriptine in Parkinson's disease: a multi-center, cross-over, controlled study. Mov Disord 1994;9:431-436.
13. Olanow CW, Fahn S, Muenter M, et al. A multicenter double-blind placebo-controlled trial of pergolide as an adjunct to Sinemet in Parkinson's disease. Mov Disord 1994;9:40-47.
14. Wolters EC, Tissingh G, Bergmans PLM, Kuiper MA. Dopamine agonists in Parkinson's disease. Neurology 1995;45-28-34.
15. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
16. Hoehn MM, Yahr MD. Parkinsonism: onset, progression, and mortality. Neurology 1967;17:427-442.
17. Fahn S, Elton R, members of the UPDRS Development Committee. Unified Parkinson's Disease Rating Scale. In: Fahn S, Marsden CD, Goldstein M, Calne DB, eds. Recent developments in Parkinson's disease. Vol. 2. New York: Macmillan, 1987:153-163.
18. Folstein MF, Folstein SE, Mc Hugh PR. "Mini Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
19. Clinical global impressions. In: Guy W, ed. ECDEU assessment, manual for psychopharmacology. Rev. ed. Rockville, MD: Department of Health, Education, and Welfare, 1976: 218-222. DHEW publication ADM 76-338.
20. Dunt DR, Kaufert JM, Corkhill R, et al. A technique for precisely measuring activities of daily living. Community Med 1980;2:120-125.
21. Wright A, Lees AJ, Stern GM. Mesulergine and pergolide in previously untreated Parkinson's disease. J Neurol Neurosurg Psychiatry 1986;49:482-484.
22. Mizuno Y, Kondo T, Narabayashi H. Pergolide in the treatment of Parkinson's disease. Neurology 1995;45:13-21.
23. Marsden CD, Fahn S. Problems in Parkinson's disease and other akinetic-rigid syndromes. In: Marsden CD, Fahn S, eds. Movement disorders 2. London: Butterworths, 1987:65-72.
24. Rascol A, Montastruc JL, Rascol O. Should dopamine agonists be given early or late in the treatment of Parkinson's disease? Can J Neurol Sci 1984;11:229-232.
25. Melamed E. Initiation of levodopa therapy in parkinsonian patients should be delayed until the advanced stages of the disease. Arch Neurol 1986;43:402-405.
26. Blin J, Bonnet AM, Agid Y. Does levodopa aggravate Parkinson's disease? Neurology 1988;38:1410-1416.
27. Adler CH, Sethi KD, Hauser RA, et al. Ropinirole for the treatment of early Parkinson's disease. Neurology 1997;49: 393-399.
28. Hubble JP, Koller AL, Cutler NR, et al. Pramipexole in patients with early Parkinson's disease. Clin Neuropharmacol 1995;18:338-347.
29. Rinne UK, Bracco F, Chouza C, et al. Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. Neurology 1997;48:363-368.
30. Blunt SB, Jenner P, Marsden CD. Suppressive effect of L-dopa on dopamine cells remaining in the ventral tegmental area of rats previously exposed to the neurotoxin 6-hydroxy-dopamine. Mov Disord 1993;8:129-133.
31. Mena MA, Davila V, Sulzer D. Neurotrophic effects of L-dopa in postnatal midbrain dopamine neuron/cortical astrocyte co-cultures. J Neurochem 1997;69:1398-1408.
32. Lees AJ, Stern GM. Sustained bromocriptine therapy in previously untreated patients with Parkinson's disease. J Neurol Neurosurg Psychiatry 1981;44:1020-1023.
33. Montastruc JL, Rascol O, Rascol A. A randomized controlled study of bromocriptine versus levodopa in previously untreated parkinsonian patients: a 3 year follow-up. J Neurol Neurosurg Psychiatry 1989;52:773-775.
34. Parkinson's Disease Research Group in the United Kingdom. Comparisons of therapeutic effects of levodopa, levodopa and selegiline, and bromocriptine in patients with early, mild Parkinson's disease: three year interim report. BMJ 1993;307: 469-472.
35. Rinne UK. Early combination of bromocriptine and levodopa in the treatment of Parkinson's disease: a 5-year follow-up. Neurology 1987;37:826-828.
36. Felten DL, Felten SY, Fuller RW, et al. Chronic dietary pergolide preserves nigrostriatal neuronal integrity in aged Fisher 344 rats. Neurobiol Aging 1992;13:339-351.
37. Yoshikawa T, Minamiyama Y, Naito Y, et al. Antioxidant properties of bromocriptine, a dopamine agonist. J Neurochem 1994;62:1034-1038.